
Shares of Tylenol maker Kenvue KVUE.N rise 4.2% to $24.08 premarket
KVUE says it earned a profit of 24 cents per share vs analysts' estimates of 23 cents per share - data compiled by LSEG
Reports Q1 revenue of $3.74 billion vs estimates of $3.67 billion
KVUE expects 2025 profit to remain flat year-over-year, anticipating higher costs from President Trump's tariffs on U.S. imports
Co had previously forecast 2025 profit to be flat to 2% growth
Separately, company appoints Amit Banati as chief financial officer, effective May 12
Up to last close, stock has risen 8.2% YTD